Board of Directors

Chan W. Galbato has served as a member of our Board since November 2025. Mr. Galbato has been serving as Senior Advisor to Barington Capital Group, LP, a private investment firm, since March 2025, and Alvarez Marsal Holdings, LLC, a consulting firm, since August 2025. Previously, he was the Chief Executive Officer of Cerberus Operations and Advisory Company, LLC, the global operating platform of Cerberus Capital Management, a private investment company, from 2012 to 2024. Prior to joining Cerberus in 2009, Mr. Galbato served as President and Chief Executive Officer of the Controls Group of Invesys plc, a global technology company. Prior to that, he served as President of Services and of the commercial distribution arm of companies for The Home Depot; President and Chief Executive Officer of Armstrong Floor Products, a division of Armstrong World Industries; Chief Executive Officer of Choice Parts, a joint venture start-up; and President and Chief Executive Officer of Coregis Insurance Company, a GE Capital company. He spent fourteen years with General Electric Company, holding several operating and finance leadership positions within their various industrial divisions. Mr. Galbato has served on the boards of directors of various companies, including The Eastern Company, a publicly traded engineering and manufacturing company, since May 2025; NFI Group Inc., a publicly-traded multinational bus manufacturer, from January 2025 to April 2025; Albertsons Companies, Inc., a publicly traded food and drug retail company, from April 2021 to October 2024; Blue Bird Corporation, a publicly-traded manufacturer of school buses and specialty vehicles, from February 2015 to April 2023; Autoweb, Inc., a publicly-traded digital marketing company for the automotive industry, from January 2019 to May 2022; and Avon Products, Inc., a publicly-traded cosmetics and beauty company, from March 2016 to January 2020. Mr. Galbato holds a B.A. in Economics from the State University of New York and an M.B.A. from the University of Chicago.

Class I Director, Term Expires 2028

James M. Hindman has served as a member of our Board since September 2019. Mr. Hindman had served in various positions at Allergan, Inc. (“Allergan”), a multi-specialty healthcare company, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President and Chief Financial Officer of Allergan from August 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations from March 2002 to August 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of Aatru Medical and Amolyt Pharma SAS. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics, a privately held biotechnology company, from December 2017 to December 2018. Mr. Hindman currently serves as a member of the Board of Regents at Loyola Marymount University and serves as a member of the Dean’s Executive Council for the College of Business Administration at Loyola Marymount University. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a Certified Public Accountant in the state of California (inactive).

Class III Director, Term Expires 2027

Beverly Huss has served as a member of our Board of Directors since January 2018. From 2021 to 2023, she has served as Chief Executive Officer of Pagonia Medical, Inc., a private company focused on creating a novel non-invasive device for the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions. Prior to Pagonia, Ms. Huss served as President and Chief Executive Officer of Qool Therapeutics, Inc., formerly Thermocure, Inc., a privately held development stage company focused on temperature management therapies. Prior to joining Qool, Ms. Huss was President and Chief Executive Officer at start-up medical device company Vibrynt, Inc., and held multiple senior level leadership positions at Guidant Corporation, including, most recently President, Endovascular Solutions, and Vice President, Global Marketing, Vascular Intervention and Vice President of the Stent Business Unit. 

Ms. Huss also currently serves on the boards of Ancora Heart, Inc., Vicarious Surgical Inc., Iridex Corporation, Infusystem Holdings, Inc., and Clarius Healthcare. Her prior public company board experience includes Artes Medical, Wright Medical Group, and Dade Behring, Inc.

Class II Director, Term Expires 2026

Steve La Neve serves as Chief Executive Officer of Accuray, bringing over 40 years of global experience in medical technology and biotechnology, spanning capital equipment and implantable devices. He is recognized for driving operational excellence and delivering sustained value creation.

Prior to Accuray, Steve held several senior executive roles, including President of Globus Medical Japan K.K. and President of Globus Medical Trauma and Joint Reconstruction, a leading musculoskeletal technology company. He also served as Global Sector President for Medtronic’s Spine and Biologics Division. Across these roles, Steve consistently optimized operations, managed costs, achieved financial targets, and expanded revenue streams through innovative technology platforms.

Steve also served as CEO and Board Director of Bone Biologics Corporation, and as President & CEO of ETEX Corporation, where he led the successful sale of the business to a global leader in joint reconstruction. As Global President of Pre-Analytical Systems at Becton Dickinson, he drove revenue and profit growth that outpaced market performance.

Steve holds an MBA from West Chester University and a Bachelor of Science in Health Planning and Administration from Pennsylvania State University. He is a member of Omicron Delta Epsilon, an international honor society recognizing academic excellence and achievements in economics.

Class III Director, Term Expires 2027

Anne B. Le Grand has served as a member of our Board since July 2020. Ms. Le Grand has served as a consultant to IBM Watson Health, a machine intelligence company that is a division of the International Business Machines Corporation (“IBM”), an information technology company. Prior to that, Ms. Le Grand also served as Vice President and General Manager of Imaging, Life Sciences, Oncology and Genomics at IBM Watson Health from July 2019 to December 2020 and VP and General Manager of Imaging at IBM Watson Health from April 2016 to July 2019. Prior to her roles at IBM Watson Health, Ms. Le Grand served as Senior Vice President of Healthcare and General manager of Therapeutics from January 2015 to April 2016 and Senior Vice President of Healthcare Business Transformation from January 2014 to January 2015 at Philips, a health technology company. Ms. Le Grand previously served in various senior leadership positions at GE Healthcare and Eastman Kodak Company and began her career at 3M Company in the Medical Imaging Division. Ms. Le Grand holds a B.S. in Chemistry from Queens University of Charlotte.

Class I Director, Term Expires 2028

Steven F. Mayer has served as a member of our Board since June 2025 and was appointed to Transformation Board Sponsor in October 2025. Currently, Mr. Mayer serves as Chairman of the Operations Advisory Council and senior advisor to the private credit group of TCW, a $200 billion investment group, and senior strategic advisor to Red Arts Capital, a private equity firm focused on supply chain investments. Previously, Mr. Mayer was the Executive Chairman of Grifols, SA, a publicly traded global healthcare company, and Co-Head of Global Private Equity and Chairman of the Investment Committee of Cerberus Capital Management, L.P., a private investment firm with approximately $60 billion of capital under management. He has extensive governance experience, having served as a member of the Boards of Directors of more than 30 other public and private companies spanning a range of industries including medical technology and biotherapeutics. Mr. Mayer holds a Juris Doctor (JD) degree from Harvard Law School and a Bachelor of Arts degree in public policy analysis from Princeton University.

Class III Director, Term Expires 2027

Mika Nishimura has served as a member of our Board since August 2021. Since 2011, Ms. Nishimura has served as an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund. She also serves as a board member of Hoya Corp. (Tokyo Stock Exchange Prime: 7741), a board member of SI-BONE, Inc. (NASDAQ: SIBN), a public medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, and as a board advisor to Tristel, plc, a UK public medical technology company. From 2015 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical-stage medical device company acquired by Boston Scientific. Previously, she served as Vice President, Commercial Development at Auxogyn Incorporated, a medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Incorporated, where she held P&L responsibilities for the emerging markets. Ms. Nishimura has an MBA from Harvard Graduate School of Business Administration and a B.A. in Economics from Yale University.

Class II Director, Term Expires 2026

Joseph E. Whitters has served as a member of our Board of Directors since July 2018 and Chairperson of our Board since January 2021. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in various capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previously served as the Controller for United Healthcare Corp. from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Previously, Mr. Whitters served on the boards of directors and audit committees of various public companies, including Cutera Inc., Spark Networks SE, Analogic Corporation, InfuSystem Holdings, Inc. and PRGX Global, Inc. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College.

Class I Director, Term Expires 2028